# Sorafenib in Treating Non-Smokers or Former Light Smokers With Relapsed or Refractory Stage IIIB or Stage IV Non-Small Cell Lung Cancer

> **NCT00754923** · PHASE2 · TERMINATED · sponsor: **Ohio State University Comprehensive Cancer Center** · enrollment: 11 (actual)

## Conditions studied

- Lung Cancer

## Interventions

- **DRUG:** sorafenib

## Key facts

- **NCT ID:** NCT00754923
- **Lead sponsor:** Ohio State University Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-10
- **Primary completion:** 2012-04
- **Final completion:** 2012-04
- **Target enrollment:** 11 (ACTUAL)
- **Last updated:** 2019-03-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00754923

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00754923, "Sorafenib in Treating Non-Smokers or Former Light Smokers With Relapsed or Refractory Stage IIIB or Stage IV Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00754923. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*